Rna Diagnostics Inc.
Laura Pritzker has a diverse work experience spanning over two decades. Laura started their career as a Postdoctoral Fellow at the University of Washington in 2000 and continued in this role until 2004. Laura then worked as Postdoctoral Fellow at The Hospital for Sick Children from 2004 to 2006. In 2008, Laura joined Xceed Molecular as a Research Associate for a brief period of five months. Laura later joined Rna Diagnostics Inc. in 2010 as Principal Scientist, a role they held until 2017. From 2017 to 2021, Laura served as the Director of Operations and R&D at Rna Diagnostics Inc. Currently, they hold the position of VP Operations and R&D at the same company.
Laura Pritzker has a strong education background in clinical biochemistry. Beginning in 1993, they pursued their Master of Science degree in Clinical Biochemistry at the University of Toronto, which they completed in 1996. Subsequently, Laura continued their academic journey at the same institution and pursued a PhD in Clinical Biochemistry from 1996 to 2000.
This person is not in any teams
Rna Diagnostics Inc.
Rna Diagnostics is an early-stage molecular diagnostics company developing medical diagnostic tools to assist in the management of cancer. The company's first product, the RNA Disruption AssayTM (RDATM), is a novel test that helps oncologists rapidly assess the effectiveness of cancer chemotherapy.